Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia

Trial Profile

Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs Flortaucipir-F-18 (Primary)
  • Indications Primary progressive aphasia
  • Focus Pharmacodynamics
  • Acronyms SLD3
  • Most Recent Events

    • 15 Oct 2017 Last checked against ClinicalTrials.gov record.
    • 07 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 15 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top